source
- Typewriter secures $56M to advance jumping-gene platform and in vivo CAR-T therapiesTypewriter, a biotech startup, announced it has closed a $56 million financing round. The capital will be used to develop its jumping-gene platform, which seeks to deliver full genes without viral…
- Alumis' TYK2 inhibitor flunks mid-stage lupus trial, shares drop 55%Alumis reported that its experimental TYK2 inhibitor, envudeucitinib, failed to meet any primary or secondary endpoints in a mid-stage study of systemic lupus erythematosus. The company highlighte…